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Hyporesponsiveness, or resistance, to antiplatelet therapy may be a major contributor to poorer outcomes
among cardiac patients and may be attributed to an array of mechanisms—both modifiable and
unmodifiable. Recent evidence has uncovered clinical, cellular, and genetic factors associated with
hyporesponsiveness. Patients with severe acute coronary syndromes (ACS), type 2 diabetes, and increased
body mass index appear to be the most at risk for hyporesponsiveness. Addressing modifiable mechanisms
may offset hyporesponsiveness, while recognizing unmodifiable mechanisms, such as genetic
polymorphisms and diseases that affect response to antiplatelet therapy, may help identify patients who are
more likely to be hyporesponsive. Hyporesponsive patients might benefit from different dosing strategies or
additional antiplatelet therapies. Trials correlating platelet function test results to clinical outcomes are
required. Results from these studies could cause a paradigm shift toward individualized antiplatelet therapy,
improving predictability of platelet inhibition, and diminishing the likelihood for hyporesponsiveness.
Key words: catheterization/diagnostic interventional<cardiac, platelets, acute coronary syndromes<ischemic
heart disease, myocardial infarction<ischemic heart disease, thrombosis/hypercoagulable states
Introduction
Hyporesponse (or resistance) to antiplatelet therapies has
been increasingly recognized in recent years; suboptimal
response to aspirin (ASA) and other antiplatelet therapies
involves multiple underlying clinical, cellular, and genetic
mechanisms, some of which are modifiable and others
which are not. Effective intervention against modifiable
mechanisms offers an obvious strategy to counteract
hyporesponsiveness. Alternatively, better understanding
of unmodifiable mechanisms of hyporesponse, such as
genetic polymorphisms and diseases that affect response to
antiplatelet therapy, can proactively identify patients who are
more likely to respond suboptimally to platelet inhibitors,
and thus, those who might benefit from different dosing
strategies or additional antiplatelet therapies. Recognition
of the multifactorial causes of hyporesponse can guide
clinicians toward antiplatelet strategies that offer patients
with acute coronary syndrome (ACS) the best chance for
better outcomes. In this article, hyporesponsiveness to ASA
and clopidogrel is assessed by exploring its causes and
patient characteristics that are predictive of suboptimal
response to platelet inhibition.
Investigations of Hyporesponse with Platelet Inhibitors
As pointed out earlier in this supplement, antiplatelet
therapies have been shown to reduce ischemic events.1–5
Also, as has been discussed, hyporesponse to antiplatelet
therapy, regardless of the reason, may increase the
likelihood of poor clinical outcome. In this section, we
review various etiologies underlying hyporesponsiveness to
antiplatelet therapy.
Aspirin
Several recent studies now support the association between
ASA resistance and poorer clinical outcomes, including the
aforementioned findings by Eikelboom and colleagues of
increased risk of adverse outcomes in patients with rel-
atively elevated baseline urinary 11-dehydro-thromboxane
B2 (UDTB) levels6 and Chen and colleagues of increased
markers of myonecrosis in ASA hyporesponsive patients.7
Received: November 20, 2007
Accepted: November 27, 2007
Clin. Cardiol. (Suppl. 1) 31, 3, I-21–I-27 (2008) I-21
Published online in Wiley InterScience. (www.interscience.wiley.com)
DOI:10.1002/clc.20360  2008 Wiley Periodicals, Inc.
However, a number of issues have hampered the speed
and precision by which mechanisms of ASA hyporesponse
have been identified. For example, there is an absence of
consensus definitions for ASA hyporesponse. Furthermore,
categorization of ASA resistance as a dichotomous response
(rather than a continuous variable) has resulted in wide
ranges of resistance incidence reported in the literature.
Lastly, there is uncertainty concerning the stability of ASA
response in a single patient over time.8
Proposedmechanismsofhyporesponse: In many patients,
platelet activation occurs despite administration of therapeu-
tic doses of ASA. In order to differentiate mechanisms of
ASA hyporesponse, measurements of serum thromboxane
B2 and arachidonic acid-induced platelet activation were
assessed in 700 ASA-treated patients undergoing cardiac
catheterization.9 The ASA reduced thromboxane B2 levels
in all but two evaluable patients compared with untreated
controls; these patients were deemed noncompliant and
not included in analyses. The major finding was that there
is residual arachidonic acid-induced platelet activation in
patients who receive ASA. Underdosing or noncompliance
was attributed to this residual activation in only 2% of
patients. The underlying mechanism in the vast majority
of patients was a cyclooxygenase (COX)-1 and COX-2 inde-
pendent pathway for platelet activation. Multivariate analysis
showed that treatment with clopidogrel was associated with
decreased arachidonic acid-induced platelet activation, indi-
cating that this COX-independent mechanism was mediated
in part via adenosine diphosphate (ADP)-induced platelet
activation.
Evidence to support dose-dependent platelet inhibition
by ASA independent of COX-1 effects comes from the
recent Aspirin Induced Platelet Effects (ASPECT) study.10
In this double-blind, double-crossover investigation of 3
commonly used ASA doses (81, 162, and 325 mg/d),
arachidonic acid-induced aggregation was suppressed in a
dose-independent fashion whereas collagen-induced platelet
aggregation and shear-induced platelet aggregation were
significantly affected by dose. Moreover, the prevalence
of resistance measured by COX-1 nonspecific methods
such as ADP-, collagen- and shear-induced aggregation,
was also significantly affected by dose. The observation
of dose-related effects despite near complete inhibition of
arachidonic acid-induced aggregation may be explained by
non-COX-1 mediated antiplatelet properties in ASA. Finally,
the urinary levels of under-dehydrated hydrogen bonds
(UDHB) were also significantly reduced by ASA doses
higher than 81 mg/day. The latter findings may be related
to the inhibitory effects of higher dose ASA on COX-2.
An important message of the ASPECT study is that the
prevalence of ASA resistance is highly assay-dependent.
The ASA hyporesponsiveness is unlikely to result solely
from variabilities in COX pathways. Its etiology is likely
multifactorial; multiple mechanisms of ASA hyporesponse
have been proposed, and may be grouped as cellular, clinical,
and genetic (Figure 1).8 Obvious clinical factors include
a failure to prescribe antiplatelet therapies and patient
noncompliance with prescribed therapy, but also suboptimal
absorption and drug interactions. In particular, when given
concomitantly with ASA, ibuprofen has been shown to
antagonize ASA-induced irreversible platelet inhibition by
binding to the COX-1 binding site of ASA.11 Several genetic
polymorphisms have been proposed to explain varying
degrees of ASA hyporesponse. They include polymorphisms
affecting COX-1 receptors, platelet membrane proteins,
collagen receptors, and von Willebrand factor (vWF).8
Hypotheses on overcoming aspirin hyporesponse: The
Antithrombotic Trialists’ Collaboration did not recommend
daily ASA doses higher than 75–150 mg for long-term
prevention of thrombotic events in high-risk patients
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Figure 1: Potential mechanisms to explain aspirin hyporesponsiveness. Adapted with permission from Bhatt DL.8
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higher doses and had less risk of bleeding.1 Although dose-
related failure may be a cause of ASA hyporesponsiveness in
some patients, multiple factors confound direct causation of
dose and response with ASA (such as worsening thrombosis
and variability of ASA response, which can change patients’
categorization over time from hyporesponsive to responsive
or vice versa). In the Clopidogrel in Unstable Angina to
Prevent Recurrent Ischemic Events (CURE) trial population
of patients with ACS, it was found that bleeding risks were
increased with increasing ASA dose when given alone or
with clopidogrel. Higher ASA doses were not associated
with lower clinical event rates, and reductions in major
ischemic events did not vary significantly by ASA dose.12
Also, the Blockade of the Glycoprotein IIb/IIIa Receptor to
Avoid Vascular Occlusion (BRAVO) trial found that serious
bleeding was more common among patients with vascular
disease who received ASA doses of >162 mg/day.13
Substitution of another antiplatelet agent has been
proposed as a possible strategy to avoid ASA hyporesponse.
Given its different mechanism of action of inhibiting platelet
activation, clopidogrel would be the logical choice for
substitution. In vitro data have shown that platelets from
patients who are hyporesponsive to ASA exhibit greater
sensitivity to ADP.14 Also, the aforementioned findings
by Frelinger and colleagues suggest that clopidogrel
may attenuate ASA hyporesponsiveness.9 However, clinical
studies are necessary to substantiate this hypothesis and
there is clearly a clinical need to characterize further the
problem of ASA hyporesponse and provide evidence-based
solutions for patients with cardiovascular disease (CVD).
Clopidogrel
Clopidogrel response variability was first described using
flow cytometry to detect ADP-induced fibrinogen binding in
treated patients,15 with subsequent confirmation in a study
of percutaneous coronary intervention (PCI) patients using
both turbidimetric aggregometry and flow cytometry.16
Clopidogrel hyporesponsiveness appears to increase the
risk for thrombotic events, particularly in patients under-
going PCI.17 For instance, the previously mentioned study
by Matetzky and colleagues found an increased likelihood
of recurrent cardiovascular events among patients with ST-
segment elevation myocardial infarction (STEMI) who were
hyporesponsive to clopidogrel and underwent PCI.18 In a
different population of patients regarded as nonresponders
with stable angina who underwent PCI, a higher rate of
subacute stent thrombosis was identified.19 Variability in
ADP-induced aggregation is well known in patients with
coronary artery disease treated with ASA therapy.20
Patients currently taking ASA therapy with low ADP-
induced platelet aggregation who exhibit poor inhibition
by clopidogrel may therefore remain at low ischemic
risk. Thus, it was suggested that on-treatment platelet
reactivity to ADP may be a better marker of ischemic
risk than platelet inhibition.21 Most recently, increased
risk for postprocedural ischemic events was correlated
with platelet reactivity in patients who underwent PCI and
who were receiving ongoing clopidogrel therapy.22 These
studies confirm the interindividual variability of clopidogrel-
induced platelet inhibition. The clinical challenge has been
to definitively relate response variability to therapeutic
failure and determine thresholds of platelet inhibition
and posttreatment platelet reactivity necessary to prevent
ischemic outcomes.
One of the major limitations in characterizing hypore-
sponse to clopidogrel therapy has been the lack of con-
formity among definitions of suboptimal response in trials.
Multiple definitions have led to various estimates of the
prevalence for this real clinical problem whose occurrence
is associated with excessive thrombotic events in patients
with ACS and post-PCI. Unfortunately, to date, a lack of a
standard diagnostic modality and definition has hampered
the identification and thus, the treatment, of clopidogrel
hyporesponsiveness.23 Multiple factors have been proposed
to cause variability/hyporesponse to clopidogrel, including
preinterventional platelet reactivity, genetic polymorphisms,
and acute/chronic patient characteristics correlated with
hyporesponse.
Preinterventional platelet reactivity as a predictor of
hyporesponse: The use of platelet inhibition during PCI
is important to reduce the risk for thrombus formation
and events during the peri- and postprocedural intervals.
Although 600 mg loading doses of clopidogrel may obviate
the need for glycoprotein (GP) IIb/IIIa inhibition in lower-
risk patients, platelet responses to clopidogrel loading doses
vary widely. Patients who are hyporesponsive therefore
might be at increased risk for post-PCI events. Until
recently, the impact of variability in platelet reactivity on
clinical outcome during PCI had not been thoroughly
investigated in clopidogrel-treated patients. Two recent
clinical studies support the extent of platelet aggregation
at the time of PCI as a predictor of adverse postintervention
outcomes.24,25
The Excelsior study involved 802 consecutive patients
who received a 600 mg loading dose of clopidogrel prior
to undergoing elective coronary stent placement.24 Platelet
aggregation was determined immediately before PCI via
optical aggregometry and stratified into quartiles ranging
from <4% to >32%. A composite 30-day endpoint of (major
adverse cardiac event [MACE] death, MI, and need for
target lesion revascularization) was determined. Fifteen
patients (1.9%) had a MACE within 30 days of coronary
intervention. A MACE at 30 days was 0.5% in the first
two quartiles, but increased to 3.1% in the third quartile
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Figure 2: Thirty day composite of major cardiac events (MACE) according
to quartiles of platelet aggregation. Adapted with permission from
Hochholzer W et al.24
and 3.5% in the fourth quartile (p = 0.034) (Figure 2).24
Platelet aggregation exceeding the median value conferred
a 6.7 times greater risk of MACE (95% CI, 1.52–29.41; p =
0.003). Multivariate analysis revealed platelet aggregation
immediately before PCI as an independent predictor of
30-day MACE occurrence (10% increase in ADP-induced
aggregation prior to PCI was associated with an adjusted
odds ratio for 30-day MACE of 1.32 (95% CI, 1.04–1.61;
p = 0.026).
Cuisset and colleagues randomized 292 consecutive
patients with NSTEMI to determine the effect of a 600
mg clopidogrel loading dose (versus 300 mg) given at least
12 hours prior to PCI with stenting on platelet reactiv-
ity and outcomes.25 An ADP-induced platelet aggregation
and expression of the adhesion molecule P-selectin were
assessed at least 12 hours after clopidogrel administration
but before PCI. Platelet aggregation and P-selectin expres-
sion were both significantly lower in the 600 mg clopidogrel
group compared with the 300 mg group (p<0.0001 for
both values). By 1-month follow up, 18 (12%) cardiovascular
events occurred in patients who received 300 mg of clopi-
dogrel versus 7 (5%) in the 600 mg group (p = 0.02); the
difference remained significant when adjusted for poten-
tial confounding variables. The study confirmed the value
of high posttreatment platelet reactivity (HPPR) on out-
comes; in fact, HPPR was a better predictor of clinical
outcomes than the loading dose. Thus, HPPR may be useful
in identifying patients at high risk of experiencing post-PCI
events.
Together, these two studies along with the previous study
by Bliden demonstrated the clinical significance of prepro-
cedural residual platelet function after administration of
antiplatelet therapy. The Excelsior study showed variability
in platelet reactivity in response to clopidogrel, and an associ-
ation of greater residual platelet function with increased risk
for cardiovascular events. Cuisset and colleagues demon-
strated that a higher loading dose of clopidogrel achieved
more complete inhibition of platelet activity (IPA), can possi-
bly overcome hyporesponsiveness, and was associated with
greater protection against clinical events during the first
month after PCI.
Genetic/metabolic influences on clopidogrel activity:
Clopidogrel is metabolized via hepatic cytochrome P450
3A4 (CYP3A4), suggesting that variations in CYP3A4
activity may mediate platelet response variability.26,27 Lau
and colleagues sought to determine whether variations
in CYP3A4 activity contribute to clopidogrel variability
in platelet inhibition by measuring platelet aggregation
in 32 patients undergoing PCI with stenting and 35
healthy volunteers.28 According to the degree of ADP-
induced platelet aggregation, 22% and 16% were classified as
clopidogrel nonresponders, 32% and 12% as low responders,
and 47% and 72% as responders among patients and healthy
volunteers, respectively; an inverse correlation was found
between platelet activation and CYP3A4 activity (p = 0.003).
Coadministration with the CYP3A4 inducer rifampin was
found to significantly enhance clopidogrel’s inhibition of
platelet aggregation versus clopidogrel alone (p = 0.001);
in fact, 3 clopidogrel nonresponders subsequently became
clopidogrel responders after rifampin administration. This
study reaffirms the existence of interindividual variability
with platelet inhibition; in this case, due to variations in
intrinsic CYP3A4 activity. Importantly, it also suggests a
strategy for improving clopidogrel response in patients
documented to be hyporesponsive using a point-of-care
platelet function testing device.
Polymorphisms of the CYP3A4 gene have been pro-
posed to result in variable clopidogrel-mediated platelet
response.29 Five different single nucleotide polymorphisms
of CYP3A4 were examined in 82 patients receiving clopi-
dogrel maintenance therapy who were at the steady-state
phase (>1 month) of clopidogrel therapy. Carriers of the
CYP3A4 polymorphism IVS10+12A allele had reduced
GP IIb/IIIa receptor activation and increased responsive-
ness to clopidogrel (p = 0.025 and p = 0.02, respectively);
clopidogrel-naı̈ve patients with the IVS10+12A allele also
had reduced GP IIb/IIIa activation during the 24 h follow-
ing a loading dose (p = 0.025), increased platelet inhibition
(p = 0.006), and better drug response (p = 0.003). Non-
carriers of IVS10+12A were predominant in this study,
consistent with the high prevalence of patients who are
thought to be hyporesponsive to standard dosing of clopi-
dogrel.
The CYP2C19 genetic variation was also associated
with clopidogrel responsiveness in a prospective study
of healthy men treated for 7 days with clopidogrel 75
mg/day.30 Of the 28 participants, 20 were wild-type
CYP2C19 homozygotes and 8 were heterozygous for the
loss-of-function polymorphism CYP2C19. ADP-mediated
platelet aggregation decreased gradually in homozygous
participants during treatment with clopidogrel (48.9% of
baseline by day 7; p<0.001). However, no significant change
from baseline was observed in heterozygotes, and their
platelet aggregation was significantly different from that of
the homozygous group (p = 0.003). The results suggest the
importance of the CYP2C19*2 mutant allele as a contributor
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to clopidogrel response in healthy individuals, but further
study is needed to substantiate the influence of CYP2C19
genetic polymorphisms on clopidogrel response in clinical
settings.
Although the pharmacogenetic and metabolic studies
reviewed here were small and the results require confirma-
tion in larger populations, they represent the early stages of
a paradigm shift in the field. Ultimately, it is hoped that the
identification of genetic markers will allow for individualized
approaches to antiplatelet therapy.
Conditions Associated with Decreased Antiplatelet Efficacy
Several subsets of patients have been shown to have
suboptimal responses to antiplatelet therapy, among them
patients with severe ACS, type 2 diabetes, increased body
mass index (BMI), and high pre-treatment platelet reactivity
to ADP.31
The ability of clopidogrel to inhibit platelet aggregation
is affected by the severity of ACS. In a study of 72 patients
undergoing PCI (33 patients had stable angina or Braunwald
class 1 unstable angina, 39 patients had Braunwald class
2 or 3 unstable angina), all patients received 450 mg of
clopidogrel at least 3 h prior to interventions and 235 mg of
ASA before PCI. The inhibition of platelet aggregation (IPA)
was assessed prior to PCI via a point-of-care platelet analyzer.
Mean IPA was significantly lower in patients with class 2 or 3
unstable angina (19% versus 32%, p = 0.004). In multivariate
analysis, higher angina class independently predicted lower
IPA (p = 0.018). Importantly, Soffer and colleagues also
demonstrated significant interpatient variability in response
to clopidogrel loading.32
Insulin normally inhibits platelet aggregation via inhibi-
tion of the P2Y12 pathway. However, patients with type 2
diabetes have reduced responsiveness to insulin, leading to
upregulation of the P2Y12 pathway and increased platelet
reactivity, with resultant reductions in responsiveness to
antiplatelet agents.33–35 The impact of insulin therapy on
platelet dysfunction was evaluated in patients with CAD who
were taking ASA and clopidogrel (201 patients with type 2
diabetes and 65 nondiabetic patients).36 Platelet aggrega-
tion was assessed using ADP (specific) and nonspecific
agonists for the P2Y12 pathway. High shear-induced platelet
reactivity also was assessed. Diabetic patients demonstrated
significant increases in platelet aggregation compared with
nondiabetic patients (p<0.0001). Insulin treatment emerged
as the strongest predictor of ADP-induced platelet aggrega-
tion; in response to P2Y12-specific stimuli with ADP, insulin-
treated diabetic patients had increased platelet aggregation
compared with diabetic patients not treated with insulin
(Figure 3).36 Collectively, the results showed that P2Y12-
specific and nonspecific pathways of platelet reactivity are


























Figure 3: Adenosine diphosphate -stimulated platelet aggregation in
noninsulin-treated type 2 diabetes (NITDM) and insulin-treated type 2
diabetes mellitus (ITDM). Reproduced with permission from Angiolillo DJ
et al.36
therapy demonstrate greater ADP-induced platelet aggrega-
tion compared to non-insulin treated patients.
Clopidogrel hyporesponsiveness is associated with sig-
nificant increases in cardiovascular events and death in
patients who undergo PCI with coronary stenting.37 Given
the alteration in antiplatelet response demonstrated in type
2 diabetics, Geisler and colleagues assessed response to
a 600 mg clopidogrel loading dose in 485 patients (161
had type 2 diabetes). Following administration of a 600
mg dose of clopidogrel, platelet response was significantly
lower in the diabetic patients compared with nondiabetic
patients (p = 0.01). For the subgroup of patients with
ACS who received coronary stenting for stable angina,
diabetic patients had significantly greater posttreatment
platelet aggregation, including ADP-induced (p = 0.002)
and collagen-induced (p = 0.005) aggregation, compared
with nondiabetic patients.38 The decreased responsiveness
to a 600 mg loading dose of clopidogrel observed in diabetic
patients with ACS suggests that diabetes impacts residual
platelet activity and places patients at increased risk for
recurrent thrombotic events.
The BMI is another factor that may cause interpatient vari-
ability with response to clopidogrel, whose dose—unlike
heparin and GP IIb/IIIa inhibitors—is not weight-adjusted.
The effect of BMI on response to clopidogrel was exam-
ined in 48 patients undergoing coronary stent implantation
who received a 300 mg loading dose of clopidogrel prior
to intervention. On the basis of BMI, 60% of patients were
overweight (BMI  25) and 40% were normal weight (BMI
<25). The ADP-induced platelet aggregation was signifi-
cantly greater in overweight patients at baseline, at 24 h,
and during the overall time period. Platelet inhibition at 24
hours was suboptimal (<40%) in 59% of overweight patients
compared with 26% of normal-weight patients (p = 0.04);
elevated BMI was the only independent predictor of sub-
optimal platelet response. The data suggest that there is
higher platelet function in overweight patients and that these
patients might require a higher loading dose of clopidogrel
or other adjunctive therapies to achieve adequate inhibi-
tion of platelet aggregation early after coronary stenting.39
Similar findings were reported in a recent study of 402
patients.40
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Hyporesponsiveness to Dual Antiplatelet Therapy
The dual antiplatelet therapy with ASA and clopidogrel
has become part of standard care for patients undergoing
PCI. The variability in platelet response has been observed
with each drug, but variability in the response to their
combination has not been studied extensively. In a study of
50 patients pretreated with ASA and clopidogrel prior to PCI,
five (10%) exhibited hyporesponse to both agents.41 The
small size notwithstanding, the study offered a suggestion
of hyporesponsiveness to dual agents in a subset of
patients.
The concept of hyporesponsiveness to dual agents was
further evaluated in 150 elective PCI patients who had
received ASA for  1 week and bivalirudin at the time
of intervention.42 Immediately after PCI, patients received
300 mg clopidogrel and 325 mg ASA, followed by 75 mg
clopidogrel and 325 mg ASA daily. Hyporesponse ASA
was defined as having 2 or 3 of the following criteria:
rapid platelet function analyzer-ASA score  500, 5µmol/L
ADP-induced aggregation  70%, and 0.5 mg/mL arachi-
donic acid-induced aggregation  20%. Hyporesponse to
clopidogrel was defined as baseline minus posttreatment
aggregation  10% in response to 5 and 20µmol/L ADP.
By those criteria, 12.7% of patients were hyporespon-
sive to ASA and 24% to clopidogrel. Forty-seven per-
cent of ASA-hyporesponsive patients were also hypore-
sponsive to clopidogrel. Possible mechanisms for this
dual hyporesponse proposed by the authors included the
following:
• Broad increases in platelet reactivity to all platelet
agonists
• Diabetes: More than 50% of patients in the ASA-
resistant group were diabetic
• Increased platelet turnover in ASA-hyporesponsive
patients may lead to the formation of young platelets
that are able to form thromboxane A2 and are ADP-
hyporesponsive
Hyporesponsiveness to dual agents might identify
patients who have an even greater risk of thrombotic com-
plications compared with patients having hyporesponse to
only one platelet inhibitor. The CK-MB elevation following
PCI is a marker of increased risk for death, MI, and repeat
revascularization; indeed, patients in this study who were
hyporesponsive to either antiplatelet agent were more likely
to have elevated CK-MB levels following stent implanta-
tion. Patients who were hyporesponsive to dual agents had
a 2-fold increase in the rate of myonecrosis versus dual
drug-sensitive patients.42
Conclusion
Suboptimal response to antiplatelet therapies likely has a
multifactorial etiology, which has yet to be fully elucidated.
As the field progresses, more options may become available
to address this real clinical problem, whether they be novel
approaches with currently available platelet inhibitors or
new antiplatelet compounds. There is a clear need for larger
trials whose objective is to definitively correlate results from
tests of platelet function to clinical outcomes. In the future,
results from these investigations could potentially cause a
shift in paradigm toward individualized antiplatelet therapy,
which confers more predictable platelet inhibition and less
chance for hyporesponsiveness.
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M, et al.: Platelet aggregation according to body mass index in
patients undergoing coronary stenting: should clopidogrel loading-
dose be weight adjusted? J Invasive Cardiol 2004;16:169–174
40. Sibbing D, von Beckerath O, Schömig A, Kastrati A, von
Beckerath N: Impact of body mass index on platelet aggregation
after administration of a high loading dose of 600 mg of
clopidogrel before percutaneous coronary intervention. Am J
Cardiol 2007;100:203–205
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